Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
In 2014, tests based on the detection of mycobacterial lipoarabinomannan (LAM) antigen in urine emerged as point-of-care tests for tuberculosis (TB). LAM antigen is a lipopolysaccharide present in mycobacterial cell walls, which is released from metabolically active or degenerating bacterial cells and appears to be present only in people with ...
Diagnosing active tuberculosis based only on signs and symptoms is difficult, [99] as is diagnosing the disease in those who have a weakened immune system. [100] A diagnosis of TB should, however, be considered in those with signs of lung disease or constitutional symptoms lasting longer than two weeks. [100]
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
Nodules and fibrotic scars may contain slowly multiplying tubercle bacilli with the potential for future progression to active tuberculosis. [1] Persons with these findings, if they have a positive tuberculin skin test reaction, should be considered high-priority candidates for treatment of latent infection regardless of age.
Aspergilloma in an old tuberculosis cavity; healed, calcified tuberculous lesions are also present towards the right of the image Healed tuberculous cavity, where the entire left lung is destroyed. Post-tuberculosis lung disease (PTLD) is ongoing lung disease that is caused by tuberculosis (TB) but persists after the infection is cured. [1]
The treatment of latent tuberculosis infection (LTBI) is essential to controlling and eliminating TB by reducing the risk that TB infection will progress to disease. Latent tuberculosis will convert to active tuberculosis in 10% of cases (or more in cases of immune compromised patients).
In December 2010, the World Health Organization (WHO) endorsed the Xpert MTB/RIF for use in tuberculosis (TB) endemic countries. [3] The announcement followed 18 months of assessing its field effectiveness in tuberculosis, MDR-TB, and TB/HIV co-infection. [4] The test may enable the diagnosis of TB in patients likely to be missed by traditional ...